In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters.
Jacek Piatek, Hanna Krauss, Arleta Ciechelska-Rybarczyk...
https://pubmed.ncbi.nlm.nih.gov/32403297/Actively Recruiting
Led by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz · Updated on 2025-12-17
20
Participants Needed
2
Research Sites
25 weeks
Total Duration
Researchers are evaluating the effects of a nine-strain synbiotic called Vivatlac Synbiotikum on the gut microbiota of patients with Irritable Bowel Syndrome IBS. This multi-center, randomized, double-blind, placebo-controlled trial includes IBS patients diagnosed using the World Gastroenterology Organisations questionnaire and with moderate to severe symptoms assessed by the IBS Severity Scoring System IBS-SSS. Participants undergo a four-week screening phase without treatment to track IBS symptoms and stool characteristics using a diary. Then, they are randomly assigned to receive either one capsule daily of Vivatlac Synbiotic, containing nine probiotic strains and fructooligosaccharides, or a placebo capsule for 12 weeks. Treatment effects on IBS severity and gut microbiota are measured throughout the study. During the study, participants complete symptom assessments at several points, including IBS-SSS, IBS Global Improvement Scale, and stool form evaluations. Stool samples are collected before and after treatment to analyze gut bacteria and inflammation markers. The primary outcome is changes in gut microbiota composition measured by sequencing methods before and after 12 weeks of treatment. Participants are monitored closely over this period to assess treatment impact and safety.
CONDITIONS
Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients
J
Jacek Piatek, Prof. Dr.
H
Henning Sommermeyer, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 4 weeks
Participants are screened for eligibility to participate in the trial.
Participants complete a patient diary to evaluate IBS symptoms and stool characteristics during this period.
Duration - 12 weeks
Participants take one capsule daily of either Vivatlac Synbiotic or a placebo for 12 weeks to assess effects on IBS symptoms and gut microbiota.
Visits occur at the start of treatment and after 4, 8, and 12 weeks of treatment to assess symptom severity, stool characteristics, and collect stool samples.
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jacek Piatek, Hanna Krauss, Arleta Ciechelska-Rybarczyk...
https://pubmed.ncbi.nlm.nih.gov/32403297/Henning Sommermeyer, Krzysztof Chmielowiec, Malgorzata Bernatek...
https://pubmed.ncbi.nlm.nih.gov/38794741/Henning Sommermeyer, Jacek Piątek
https://pubmed.ncbi.nlm.nih.gov/39065261/Henning Sommermeyer, Hanna M Pituch, Dorota Wultanska...
https://pubmed.ncbi.nlm.nih.gov/34070727/J Piatek, H Sommermeyer, M Bernatek...
https://pubmed.ncbi.nlm.nih.gov/30574800/Henning Sommermeyer, Krzysztof Chmielowiec, Malgorzata Bernatek...
https://pubmed.ncbi.nlm.nih.gov/39599697/The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Lead Sponsor